Women with HER2-positive breast cancers, which had progressed following treatment with anthracyclines, taxanes, and trastuzumab, were randomised to either capecitabine alone or capecitabine plus lapatinib with the primary end point defined as progression-free survival (PFS). Here, ERBB2 is linked to breast cancer.